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ABSTRACT 138 
Background Common diseases such as coronary heart disease (CHD) are complex in etiology. The 139 
interaction of genetic susceptibility with lifestyle factors may play a prominent role. However, gene-140 
environment interactions for CHD have been difficult to identify. Here, we investigate interaction of 141 
smoking behavior, a potent lifestyle factor, with genotypes that have been shown to associate with 142 
CHD risk.  143 
Methods We analyzed data on 60,919 CHD cases and 80,243 controls from 29 studies for gene-144 
smoking interactions for genetic variants at 45 loci previously reported to associate with CHD risk. 145 
We also studied 5 loci associated with smoking behavior. Study specific gene-smoking interaction 146 
effects were calculated and pooled using fixed-effects meta-analyses. Interaction analyses were 147 
declared to be significant at a P-value < 1.0x10-3 (Bonferroni correction for 50 tests).  148 
Results We identified novel gene-smoking interaction for a variant upstream of the ADAMTS7 gene. 149 
Every T allele of rs7178051 was associated with lower CHD risk by 12% in never-smokers (P-value: 150 
1.3x10-16) compared to 5% in ever-smokers (P-value: 2.5x10-4) translating to a 60% loss of CHD 151 
protection conferred by this allelic variation in people who smoked tobacco (Interaction P-value: 152 
8.7x10-5). The protective T allele at rs7178051 was also associated with reduced ADAMTS7 153 
expression in human aortic endothelial cells and lymphoblastoid cell lines. Exposure of human 154 
coronary artery smooth muscle cells to cigarette smoke extract led to induction of ADAMTS7. 155 
Conclusion Allelic variation at rs7178051 that associates with reduced ADAMTS7 expression 156 
confers stronger CHD protection in “never-smokers” compared to “ever-smokers”. Increased 157 
vascular ADAMTS7 expression may contribute to the loss of CHD protection in smokers.    158 
Key words: Gene-smoking interaction, gene-environment interaction, coronary heart disease, 159 
ADAMTS7, smoking. 160 
Word count: 269 161 
 162 
  163 
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Clinical Perspective 164 
1) What is new?  165 
 166 
• Using data on 60,919 CHD cases and 80,243 controls, this study conducted gene-167 
environment interaction analyses to investigate effect modification by smoking behavior at 168 
established CHD and smoking related loci. 169 
• Cardio-protective effects associated with allelic variation at the ADAMTS7 locus were 170 
attenuated by 60% in people who smoked tobacco compared to those who did not smoke. 171 
• Allelic variation at ADAMTS7 associated with reduced CHD risk was associated with reduced 172 
ADAMTS7 expression in human aortic endothelial cells and lymphoblastoid cell lines. 173 
• Exposure of human coronary artery smooth muscle cells to cigarette smoke extract led to 174 
induction of ADAMTS7. 175 
 176 
2) What are the clinical implications?  177 
 178 
• These human genomic data provide new insights into potential mechanisms of CHD in 179 
cigarette smokers.  180 
• Findings from this study also point towards the directional impact of the ADAMTS7 locus on 181 
CHD. 182 
• ADAMTS7 and its substrates have a specific role in cigarette smoking related CHD. 183 
• Inhibition of ADAMTS7 is a novel potential therapeutic strategy for CHD that may have 184 
particular benefits in individuals who smoke cigarettes. 185 
 186 
 187 
 188 
 189 
 190 
 191 
 192 
 193 
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INTRODUCTION 194 
Coronary heart disease (CHD) is a complex disorder resulting from the interplay of lifestyle 195 
and genetic factors.1, 2 Yet, gene-environment interactions for CHD have been difficult to identify. 196 
Cigarette smoking is one of the strongest lifestyle risk factors for CHD but the underlying molecular 197 
mechanisms of CHD in humans who smoke remain uncertain.3-5  Cigarette smoking accounts for 198 
one-fifth of all CHD events globally and is responsible for ~1.6 million deaths attributable to CHD 199 
annually.6 Genome-wide association studies (GWAS) have improved our understanding on the 200 
genetic predisposition to both CHD and smoking behavior.7-10 Joint or interactive effects of genetic 201 
variation and smoking behavior in the etiology of CHD, however, remain poorly understood. GWAS 202 
can provide new opportunities to investigate gene-smoking interactions.  203 
We hypothesized that genetic predisposition to CHD is modified by cigarette smoking at 204 
loci discovered by GWAS to be associated with either CHD or smoking behavior. We conducted a 205 
focused experiment at 50 main-effect loci (45 for CHD and 5 for smoking behavior) using genetic 206 
data and information on smoking behavior in 60,919 CHD cases and 80,243 controls from 29 207 
different studies. We report novel findings on gene-smoking interactions in CHD.  208 
 209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
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METHODS 221 
Summary of study Design  222 
All studies participating in the CARDIoGRAMplusC4D consortium7-9 that had information 223 
available on smoking status, CHD risk and genotypes at the 50 CHD and smoking behavior-224 
associated loci were invited to participate. The current study had five inter-related components 225 
(Supplementary Figure-1). First, as part of the quality control, we investigated the association of 226 
smoking status with CHD risk within each study. Second, we performed an updated analysis of all 227 
the SNPs (± 50 KB) at the 45 established CHD loci to identify the variant with the strongest CHD 228 
association in our study population at each established CHD locus. Effect estimates from each study 229 
in association with CHD risk were obtained and pooled to identify the strongest CHD associated 230 
variant (“lead variant”). Third, we investigated gene-smoking interactions at these 45 CHD loci and at 231 
5 loci related to smoking behavior. Fourth, for loci demonstrating differential CHD associations by 232 
smoking status, we mapped the interaction region, examined linkage disequilibrium (LD) across the 233 
region and performed conditional analyses to identify independent genetic signals. Finally, for loci 234 
exhibiting gene-smoking interaction in CHD, we assessed eQTL data for association of variants with 235 
expression of local genes in available datasets and examined expression of these genes in multiple 236 
cell types that play prominent roles in smoking-CHD pathobiology.  237 
Harmonization of phenotypes and genotypes 238 
Summary level estimates for each study were shared via a secure FTP site. We used 239 
“ever-smoking” as a primary exposure and data were harmonized by uniformly characterizing 240 
participants in each study into two categories, “ever-smokers” and “never-smokers”. “Ever-smokers” 241 
were defined as those who had smoked more than 100 cigarettes in a lifetime. For case-control 242 
studies, information on “ever smoking” status collected at the time of enrollment was used for the 243 
current analyses; whereas for prospective cohort studies, information on smoking status obtained at 244 
the baseline visit was used for the current investigation. CHD was defined based on evidence from 245 
angiography or history of verified myocardial infarction (MI), percutaneous coronary interventions 246 
(PCI) or coronary artery bypass grafting (CABG) as published in CARDIoGRAMplusC4D projects.7-9  247 
Genotype data generated through GWAS (directly genotyped or imputed) or cardio-metabochip 248 
(directly genotyped only) arrays were obtained from each study and all genetic data were aligned 249 
using the build-37 reference panel. Imputed SNPs were removed if they had any of the following: (i) 250 
a minor allele frequency of <1%; (ii) info score of <0.90; or (iii) confidence score <0.90. For each 251 
study, GWAS data were imputed using the Phase II CEU HapMap reference population.11 Standard 252 
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quality control criteria were applied by each participating study, as described previously.7 All 253 
participating studies in the CARDIoGRAMplusC4D consortium were approved by their locally 254 
relevant institutional review boards and all participants gave written informed consent before their 255 
enrollment in each study. 7-9 256 
STATISTICAL ANALYSIS 257 
Gene-smoking interaction analyses 258 
Initial quality control and association of established CHD loci with CHD risk: As part of an initial 259 
quality control, effect estimates from each study were obtained for “ever-smoking” status and CHD 260 
risk using a case-control logistic regression model adjusted for age and sex. Each participating study 261 
also assessed and, if needed, controlled for population stratification by including principal 262 
components as covariates in the regression model as described earlier.7-9 To identify variant(s) with 263 
the most significant association with CHD risk at established CHD loci in our study population, 264 
logistic regression analyses were conducted by each participating study for all the SNPs flanking 265 
(±50 kb) the lead variant previously reported at each CHD locus.  Effect estimates and standard 266 
errors were obtained and meta-analyzed using a fixed-effects inverse variance approach. All lead 267 
variants identified through these analyses were further investigated for gene-smoking interactions in 268 
CHD. One lead variant per locus was selected for primary gene-smoking interaction analyses. 269 
Investigation of the APOE locus: Although APOE has been recently established as a GWAS locus,7 270 
previous studies prior to GWAS have suggested that CHD risk is higher among carriers of the ε4 271 
allele at the APOE locus in smokers than in non-smokers.12-14 Because the ε2, ε3 and ε4 alleles at 272 
the APOE locus are not captured by the GWAS platform, we specifically conducted genotyping for 273 
rs429358 and rs7412 variants to capture the three epsilon (ε) alleles in 13,822 participants (including 274 
7,286 first-onset myocardial infarction cases) in the PROMIS study.15  275 
Gene-smoking interaction analyses at CHD and smoking loci: To assess gene-smoking interactions, 276 
analyses were conducted within each study, adjusted for age, sex and other study specific 277 
covariates (e.g., principal components), and variants were analyzed in association with CHD 278 
separately in “ever-smokers” and “never-smokers”. Results from the two groups were then used to 279 
test for interaction within each study. For the 50 variants, an interaction test statistic was calculated 280 
within each study using the following equation as adapted from Teslovich TM et.al.16  281 
(βn −  βe) 
√𝑆𝐸𝑛2 + 𝑆𝐸𝑒2
 282 
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where βn and βe are the beta coefficients for the SNP in never-smokers and ever-smokers 283 
respectively, 𝑆𝐸𝑛 and 𝑆𝐸𝑒 are the standard errors for the log-ORs estimated for never-smokers and 284 
ever-smokers, respectively. Study specific interaction beta(s) and se(s) were calculated within each 285 
study and were pooled across studies using a fixed-effects meta-analysis. Interaction analyses were 286 
declared to be significant at a P-value of <1.0x10-3 (Bonferroni correction for 50 tests).  287 
Conditional analyses on chr.15q25.1: At chr.15q25.1, we observed two variants exhibiting gene-288 
smoking interactions for CHD. The proximity of these two signals raised the possibility that the 289 
observed interactions may represent a single interaction locus across the entire region. To 290 
investigate this possibility we undertook conditional analyses using an approximate conditional and 291 
joint analyses approach, also known as GCTA (Genome-wide Complex Trait Analysis), as described 292 
previously.17-22 Briefly, this method leverages summary-level statistics from a meta-analysis and uses 293 
LD corrections between SNPs estimated from a reference sample.  Such an approach has been 294 
shown to yield similar results to that obtained from conditional analyses conducted on individual 295 
participant data and has been successfully implemented in several other studies that have fine-296 
mapped loci for other complex traits.17-22 Using this approach, we first conducted separate 297 
conditional analyses at the chr.15q25.1 locus to identify main-effect variant(s) independently 298 
associated with CHD and smoking behavior, respectively. We used the meta-analyzed data for CHD 299 
main effects in the CARDIoGRAMplus4D consortium to identify SNPs independently associated with 300 
CHD risk and we used the genetic meta-analysis data from the Tobacco and Genetics Consortium 301 
(TGC) in 140,000 participants to identify variants independently associated with smoking behavior. 302 
We then estimated the effects of these independent variants on CHD risk stratified by smoking 303 
status and mutually adjusted the effects of these variants for each other.  304 
  305 
Analysis of eQTLs and regulatory features at the chr15q25.1 gene-smoking interaction locus 306 
eQTL analyses: We mined publicly available databases to identify genotype-related expression 307 
differences (eQTLs) in ADAMTS7 and the CHRNB4-A3-A5 gene cluster in order to understand the 308 
directionality of the association of expression of these genes with CHD and smoking behavior. 309 
Specifically, we investigated data available from the GTEx consortium,23 the HapMap consortium 310 
(restricted to European populations),` and the Multiple Tissue Human Expression Resource 311 
(MuTHER).24 We also analyzed expression data in 147 donor HAoEC lines.25 We used a nominal P-312 
value of 0.002 to account for multiple testing involved in the eQTL analyses. 313 
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Regulatory features of the chr. 15q25.1 region: Data from ENCODE26 were explored as described in 314 
eMethods. ChIP-seq experiments were performed on confluent HCASMC (Cell Applications 350-05a 315 
& Lonza CC-2583; cultured in SmGM-2 BulletKit media; Lonza) as described.27 TCF21 (Abcam 316 
ab49475), Jun (Santa Cruz Biotechnology sc-1694), JunD (Santa Cruz Biotechnology sc-74), and 317 
CEBP (Santa Cruz Biotechnology sc-150) transcription factor binding was interrogated and H3K27ac 318 
data were acquired using the same ChIP protocol with an anti-H3K27ac antibody (Abcam; ab4729). 319 
Reads were aligned to the human genome (GRCh37p13) using STAR.28   320 
 321 
Analyses of ADAMTS7 and CHRNB4-A3-A5 gene expression in vascular cells and tissues 322 
ADAMTS7 and CHRNB4-A3-A5 gene expression in vascular cells: ADAMTS7 and CHRNB4-A3-A5 323 
mRNA levels were measured in cultured human coronary artery smooth muscle cells (HCASMC; 324 
Lonza CC-2583, Lonza Walkersville, MD), human coronary artery endothelial cells (HCAEC, Lonza 325 
CC-2585), human aortic smooth muscle cells (HAoSMC, Lonza CC-2571), human aortic endothelial 326 
cells (HAoEC, Lonza CC-2535), human aortic adventitial fibroblasts (HAoAF, Lonza CC-7014), and 327 
human acute monocytic leukemia cell line (THP-1, ATCC TIB-202). Further details are provided in 328 
eMethods. 329 
ADAMTS7 and CHRNB4-A3-A5 gene expression in response to cigarette smoke extract: HCASMC 330 
were grown to confluence and cigarette smoke extract experiments performed at passage-7. 331 
Cigarette smoke extract was custom-prepared by Arista Laboratories (Richmond, VA). Briefly, the 332 
condensate was generated by smoking Marlboro Red King Size Hard Pack cigarettes on an 333 
analytical smoke machine under International Organization for Standardization smoking conditions. 334 
The smoke condensate was collected on 92 mm filter pads and extracted from each pad in DMSO 335 
by shaking to obtain a solution of ~20 mg/mL final concentration of the total particulate matter. 336 
Serum starved (24 hrs) HCASMC were treated with 0.5% or 1.0% cigarette smoke extract (v/v) for 4, 337 
12, and 24 hrs in serum reduced conditions (0.5% FBS in DMEM). Details on RNA preparation and 338 
q-PCR are provided in Supplementary Methods. 339 
 340 
 341 
 342 
 343 
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RESULTS 344 
Description of the participating studies  345 
Of the 37 studies participating in the CARDIoGRAMplusC4D consortium, information on 346 
“ever-smoking” was available in 30 studies, yielding a total sample size of 60,919 CHD cases and 347 
80,243 controls. All studies recruited participants of European ancestry, except PROMIS (South 348 
Asian),15 LOLIPOP (South Asian)29 and FGENTCARD (Lebanese).30 Number of CHD cases and 349 
controls and percentages that were “ever-smokers” are provided in Supplementary Table 1. As 350 
expected, in all the participating studies, association of “ever-smoking” status with CHD risk was 351 
directionally consistent with an increased risk of CHD (Supplementary Figure 2).  352 
New variants associated with CHD at established loci 353 
Supplementary Figure 3 and Supplementary Table 2 present effect estimates for the 354 
association with CHD for (i) the most significant variant that we identified at known CHD loci in the 355 
current CARDIoGRAMplusC4D consortium analysis as well as for (ii) the top SNP previously 356 
reported at each of these established CHD loci. Of the 45 established CHD loci, we identified 32 for 357 
which we discovered a more statistically significant SNP in association with CHD risk in our dataset 358 
than the prior reported top variant. All of these 32 SNPs were in moderate to high LD (r2 >0.6) with 359 
the previously published variants.7-9 In our primary gene-smoking interaction analyses, at each of the 360 
CHD loci, we, therefore, used the SNP with the most significant CHD association (Supplementary 361 
Figure 3 and Supplementary Table 2). Because the smoking behavior phenotype (captured as 362 
cigarettes per day [CPD]) was not available in all CARDIoGRAMplusC4D studies, we used the top 363 
variant previously reported for CPD10 at each locus (Supplementary Figure 4). 364 
Analyses of the APOE locus.  365 
The effect of rs6857, the lead CHD variant at the APOE locus, was similar in “ever-366 
smokers” compared to “never-smokers” (Supplementary Table 3).  Specifically, the CHD OR for the 367 
T allele at rs6857 was found to be 1.10 (P-value 7.93x10-4) in “never-smokers” (12,159 CHD cases 368 
and 22,932 controls) which was quantitatively similar to the CHD OR of 1.09 (P-value: 8.68x10-5) 369 
observed in “ever-smokers” (23,753 CHD cases and 24,019 controls) (interaction P-value: 0.76) 370 
(Supplementary Figure 5a). Investigation in the PROMIS study of the APOE epsilon genotypes 371 
yielded consistent findings; the OR for CHD among ε4 carriers in “never-smokers” was 1.13 372 
compared to the CHD OR of 1.07 observed in “ever-smokers” (interaction P-value: 0.82) 373 
(Supplementary Figure 5a).  374 
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Novel gene-smoking interaction effects on CHD at chromosome 15q25.1  375 
Of the 50 loci, we identified effect-modification by “ever-smoking” status on CHD risk for the 376 
lead variants at two distinct loci, rs7178051, in proximity of ADAMTS7 (an established CHD locus), 377 
and rs1051730, in proximity of CHRNB4-A3-A5 (an established smoking behavior locus) 378 
(Supplementary Table 3). Although associated with different traits and located in distinct LD blocks, 379 
these two variants reside ~224 KBs apart on chr.15q25.1 and are in weak linkage disequilibrium 380 
(LD) (r2 = 0.22), raising the question of whether these two chr.15q25.1 gene-smoking interactions on 381 
CHD are independent of each other.   382 
At the ADAMTS7 CHD locus, the T allele at the rs7178051 variant was found to be more 383 
strongly and inversely associated with CHD risk in never-smokers (OR: 0.88; P-value: 7.02x10-16) 384 
compared to a much weaker effect in ever-smokers (OR: 0.95; P-value: 8.64x10-4) (P-value of 385 
interaction: 8.57x10-5) (Table 1). Thus, the protective impact of the rs7178051 T allele observed in 386 
never-smokers was halved in people who smoked (Figure-1). This difference is not related to power 387 
differences within strata because for this variant, there were less data available in the never-smoking 388 
group (21,232 CHD cases and 38,713 controls) compared to the ever-smoking group (39,585 CHD 389 
cases and 40,749 controls). There was no substantial evidence of heterogeneity for the interaction 390 
beta across the participating studies (Heterogeneity chi-squared = 36.23 (d.f. = 25); P-value for the 391 
χ2 test of heterogeneity = 0.06; I2 = 31.0%; tau-squared (τ2 = 0). We further conducted sensitivity 392 
analyses using a random effect model; the results remained unchanged and the interaction beta 393 
remained significant (Supplementary Figure 5b). Although the frequency of rs7178051 was 39% in 394 
Europeans compared to 28% in South Asians, further analyses stratified by ancestry (i.e., European 395 
versus non-Europeans) showed similar results (Supplementary Figure 5c). Other variants 396 
discovered through prior CHD GWAS at the ADAMTS7 locus (e.g., rs7173743, rs4380028, 397 
rs3825807) were in moderate to high LD (r2 >0.50) with rs7178051 and were also found to display a 398 
similar pattern of gene-smoking interaction effects (Table 1).  399 
At the CHRNB4-A3-A5 smoking locus, the A allele at the rs1051730 variant had an inverse 400 
trend (not significant after adjustment) of association with CHD in never-smokers (OR: 0.96; P-value: 401 
1.56x10-2) and a positive trend (not significant after adjustment) in ever-smokers (OR: 1.03; P-value: 402 
1.53x10-2) (P-value of interaction: 2.37x10-4) (Table 1 and Supplementary Table 3). For this 403 
variant, data on 20,559 CHD cases and 38,198 controls were available in the never-smoking group 404 
whereas 38,923 CHD cases and 40,371 controls were available in the ever-smoking group. Similar 405 
gene-smoking interaction patterns were observed for other variants (e.g., rs2036527, rs8034191) 406 
that have been previously reported for CPD behavior at the CHRNB4-A3-A5 gene cluster (Table 1). 407 
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Further interrogation of the chr15q21.1 region encompassing rs7178051 and rs1051730 408 
across three distinct LD blocks (Figure 1) revealed multiple additional variants for which we 409 
observed gene-smoking interactions in CHD (Table 1 and Figure 1). Indeed, several SNPs (e.g., 410 
rs7178051, rs10083696, rs7176187, rs6495335, rs4887077) had genome-wide significant 411 
associations with CHD in “never-smokers” but had weaker and less significant associations with 412 
CHD in “ever-smokers” (Figure 1). Alleles clustered specifically around ADAMTS7 rather than at the 413 
CHRNB4-A3-A5 genes appear to be protective of CHD in “never-smokers” but have attenuated 414 
protective effects in “ever-smokers” (Figure 2).  415 
Conditional analyses  416 
To investigate the possibility that the two chr.15q25.1 gene-smoking interactions might 417 
represent a single interaction locus across the entire region we undertook an approximate 418 
conditional and joint analyses17-22 using summary data derived from CARDIoGRAMplus4D for CHD 419 
and from the TGC for smoking behavior. In-addition to rs7178051, we identified one other variant, 420 
rs11072794 in low LD with rs7178051 (r2=0.20) that was associated independently with CHD 421 
(Figure 3a; red triangles) (Figure 3b & Supplementary Figure 6b; red triangles). We also 422 
confirmed two variants (rs1051730 and rs684513) located in two different LD blocks that were 423 
independently associated with smoking behavior in the TGC data10 (Figure 3d & Supplementary 424 
Figure 6b; grey circles).  425 
In analyses of the CHD variants, both rs7178051 and rs11072794 remained strongly 426 
associated with CHD after adjusting for the top CPD variants (rs1051730 and rs684513) (Figure 3d, 427 
red triangles) whereas their weak association with CPD was lost after adjusting for the top CPD 428 
variants (Figure 3d; grey circles); e.g., the P-value for rs7178051 association with CPD was 1x10-5 429 
in unadjusted analyses but attenuated to 0.55 after adjusting for rs1051730 and rs684513. In 430 
analyses of the CPD variants, both rs1051730 and rs684513 remained strongly associated with CPD 431 
after adjusting for the top CHD variants (rs7178051 and rs11072794) (Figure 3b, grey circles) 432 
whereas their weak association with CHD was lost after adjusting for the top CHD variants (Figure 433 
3b, red triangles). As expected, conditional analyses that included all four of these variants resulted 434 
in a null association of the region with both CHD and CPD (Supplementary Figure 6b).  To 435 
underscore the validity of the conditional approach using summary data, we used individual 436 
participant data from an expanded PROMIS sample involving 9,025 MI cases and 8,506 controls. 437 
We found that the OR conferred by allelic variation at rs7178051 remained associated with MI risk 438 
independent of the two CPD variants (rs1051730 and rs684513) and rs11072794 (the second CHD 439 
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SNP) (Supplementary Figure 6c). Conversely, the apparent effect of allelic variation at rs1051730 440 
(the top CPD variant) on CHD risk was lost when we adjusted for the other three variants, 441 
rs7178051, rs11072794 and rs684513 (Supplementary Figure 6c). 442 
Next, using summary level data we examined the association of each of these four variants 443 
with CHD risk separately in “ever-smokers” and “never-smokers” while mutually adjusting for the 444 
other three variants (Figure 4 & Supplementary Figure 7). In these analyses, only allelic variation 445 
at rs7178051 was found to have independent genome-wide significant effects on CHD in never-446 
smokers. rs7178051 was also the only one of these four variants with significant differences in the 447 
effect estimate for gene-CHD associations between the two smoking groups (P-value for the χ2 test 448 
of heterogeneity: 5.4x10-5) after adjusting for the effects of other variants (rs11072794, rs1051730 449 
and rs684513).  These conditional analyses suggest that (a) variants located near the ADAMTS7 450 
gene but not CHRNB4-A3-A5 genes have independent effects on CHD, (b) a single independent 451 
gene-smoking interaction signal for CHD exists on chr.15q.25.1 which is localized at the ADAMTS7 452 
CHD locus (marked by rs7178051) and (c) an apparent interaction signal observed at the nearby 453 
CHRNB4-A3-A5 CPD locus (marked by rs1051730) is not independent of the ADAMTS7 454 
(rs7178051) interaction signal.  455 
To assess the robustness of conditional analyses methodology that uses summary level data 456 
(i.e., GCTA)17-22, we conducted sensitivity analyses in the PROMIS dataset (9,025 MI cases and 457 
8,506 controls). We assessed the association of rs7178051 (top CHD SNP) and rs1051730 (top 458 
CPD SNP) after mutually adjusting for each other by conducting (i) standard logistic regression using 459 
individual participant data and (ii) summary level data in PROMIS using the GCTA method 460 
(Supplementary Table 4). The top CHD SNP was found associated with CHD risk in PROMIS 461 
independent of the top CPD variant using both the methods, in-contrast the effect on CHD of the top 462 
CPD SNP attenuated sharply when adjusted for the top CHD SNP – the effect estimates obtained 463 
using the two methods were very similar (Supplementary Table 4).  464 
Finally, to further demonstrate that the gene-smoking interaction effect in CHD at rs7178051 is 465 
independent of the CHRNB4-A3-A5 CPD locus, we conducted sensitivity analyses in the PROMIS 466 
study by restricting our gene-environment interaction analysis to subjects who do not carry the minor 467 
alleles of rs1051730 and rs684513 (the two SNPs associated with CPD) at the CHRNB4-A3-A5 468 
locus. The T allele at the rs7178051 variant was associated with CHD only in never-smokers (OR: 469 
0.88; P-value: 0.01) compared to a weaker and non-significant association in ever-smokers (OR: 470 
0.94; P-value: 0.21) (Supplementary Table 5). The effect estimates obtained in each of the 471 
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categories defined by smoking status in PROMIS were similar to the effect estimates obtained in our 472 
overall meta-analyses that utilized data in all participants (Supplementary Table 5).  473 
Analysis of eQTLs and regulatory features at the chr15q25.1 gene-smoking interaction locus. 474 
We mined publicly available eQTL data from the HapMap consortium,11 GTEx consortium23 475 
and the MuTHER consortium24 as well as data from 147 HAoEC lines25 to examine the association 476 
between mRNA expression of ADAMTS7 and CHRN genes with CHD, CPD and gene-smoking 477 
interaction SNPs at the chr15q25.1 locus. SNP-mRNA associations with p-values <0.002 (correction 478 
for 20 tests) are presented (Figure 5). The top two CHD variants (rs7178051, rs11072794) are 479 
associated with reduced ADAMTS7 expression (e.g., rs11072794 p=6.01x10-21 in MuTHER LCL, 480 
n=850; and rs7178051 p=0.0029 in HAoEC, n=147) but have no association with expression of 481 
CHRN genes in any cell or tissue examined. In contrast, the top two CPD variants (rs1051730 and 482 
rs684513) were associated with CHRN gene expression (e.g., rs1051730 p=6.9x10-7 for CHRNA5 in 483 
GTEx skeletal muscle and nerve tissue) but have no association with ADAMTS7 in these cells or 484 
tissues. These findings complement conditional analyses suggesting that gene-CHD and gene-485 
smoking interaction effects on CHD are likely mediated by ADAMTS7 whereas the smoking behavior 486 
effect appears to be mediated through the CHRNA3-5 gene cluster.  487 
In analysis of data from the ENCODE project26 and for human aortic tissue in NIH 488 
Roadmap Epigenomics project, ADAMTS7 was associated with RNAseq reads and an active 489 
transcription mark, H3K36me3, whereas CHRN genes had low/absent RNAseq reads and were 490 
positive for repressive marks, H3K27me3 and H3K9me3 (Supplementary Figure 8). In HCASMC 491 
ChIPseq data, rs7178051 the top CHD and gene-smoking CHD interacting SNP, is located in a 492 
region with active regulatory marks H3K4me1 and H3K4me3 as well as transcription factor binding 493 
site for TCF21, an important HCASMC transcription factor also associated with CAD. This ChIPseq 494 
pattern was observed also in human aortic tissue (Figure 6).  These regulatory data suggest active 495 
transcription of ADAMTS7, but not CHRN genes, in vascular cells and aortic tissue and reveal that 496 
rs7178051, the lead gene-smoking CHD interaction SNP, overlaps active transcription marks and 497 
transcription factor binding regions in HCASMC.    498 
ADAMTS7 and CHRNB4-A3-A5 expression in vascular cells and their response to cigarette smoke 499 
extract  500 
In order to explore which genes at the chr15q25.1 locus are expressed in CHD-relevant 501 
vascular cells, we performed q-PCR of ADAMTS7 and the CHRNB4-A3-A5 genes in primary human 502 
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vascular cells and in the THP1 human monocyte cell line (Supplementary Figure 9 & Figure 5). 503 
Whilst ADAMTS7 mRNA was expressed abundantly in all vascular cell types, mRNA was below 504 
detection or expressed at a very low level for each of the genes in the CHRNB4-A3-A5 cluster in any 505 
of these cell types (Supplementary Figure 9). Next, we explored the effect of cigarette smoke 506 
extract on gene expression in HCASMC, a cell type of particular relevance to vascular responses to 507 
cigarette smoke products31, 32 as well as to ADAMTS7 vascular functions in atherosclerosis and 508 
CHD.33 In primary HCASMC, cigarette smoke extract exposure increased ADAMTS7 mRNA levels 509 
by over 2-fold (Figure 5) but did not affect expression of the CHRN genes (not shown).  Thus, in 510 
contrast to CHRN genes, ADAMTS7 is both expressed and modulated by cigarette smoke extract in 511 
CHD-relevant vascular cells providing biological support for ADAMTS7, but not CHRN genes, in the 512 
gene-smoking interaction at chr15q25.1.     513 
 514 
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 516 
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DISCUSSION 529 
We conducted a gene-environment interaction study at fifty loci associated with either CHD 530 
or smoking behavior and found evidence of effect-modification of genotype-related CHD risk by 531 
smoking-behavior at the chr.15q21.1 CHD locus. Specifically, we observed highly significant 532 
attenuation of the cardio-protective effects associated with alleles at this locus in people who 533 
smoked cigarettes.  Conditional analyses identified an LD block located at the ADAMTS7 gene that 534 
accounted for both the main effect on CHD as well as the gene-smoking interactions in CHD. Data 535 
from expression and cell studies support our genetic analysis, suggesting that the underlying 536 
mechanism relates to genotype differences in the effect of smoking on expression of ADAMTS7 in 537 
vascular tissue.  538 
Our findings have novel mechanistic and clinical implications. These human genomic data 539 
provide new insights into the mechanism of CHD in cigarette smokers. Identification of gene-540 
smoking interaction at the chr15q21.1 locus suggests a specific role in smoking-related CHD for 541 
ADAMTS7 and its substrates, vascular matrix and vascular smooth muscle cell biology more 542 
broadly. Such insights can help to prioritize translational strategies for smoking-related CHD and 543 
present opportunities to study lifestyle interventions and pharmacological strategies to lower CHD in 544 
individuals who smoke cigarettes. Thus, inhibition of ADAMTS7 represents a novel potential 545 
therapeutic strategy for CHD that may have particular benefits in individuals who smoke cigarettes. 546 
All smokers should receive counseling for smoking cessation yet such broad public health strategies 547 
have failed to reach or impact smoking behavior in a large portion of nicotine-addicted individuals. 548 
Our data provides a human genomic context for consideration of targeting specific genetically at-risk 549 
individuals via intensified preventive strategies and development of novel pharmacological 550 
treatments.  551 
Our study also represents a realistic strategy for performing gene-environment interaction 552 
studies using contemporary genetic data. We illustrate that identifying joint effects of genetic and 553 
lifestyle factors in CHD requires very large sample sizes, yet such analyses are biologically 554 
informative when studies are adequately powered. In this context, an important observation in our 555 
large sample is the lack of effect modification by smoking behavior on CHD at the APOE locus, a 556 
previously reported smoking interaction locus.12-14 This finding is consistent with a recent meta-557 
analysis that found no evidence of effect modification by smoking for APOE genotypes and CHD 558 
risk.34 These studies raise concerns that most prior gene-environment interactions studies in CHD 559 
have been prone to the same biases (i.e., limited statistical power and false positive associations) as 560 
18 
 
candidate gene studies investigating main effects in the pre-GWAS era. The present study differs 561 
from previous studies by being much larger and, importantly, it includes genomic and functional 562 
follow-up data supporting the plausibility of the observed gene-environment interaction. 563 
ADAMTS7 (or the A disintegrin and metalloproteinase with thrombospondin motifs-7) is a 564 
member of the ADAMTS family of secreted zinc metalloproteases.35, 36 We previously discovered 565 
and replicated genetic variation at the ADAMTS7 locus in association with coronary atherosclerosis 566 
and MI.7-9 Both in vivo and in vitro studies suggest that ADAMTS7 modulates VSMC phenotype 567 
switching and migration and that this may be mediated via cartilage oligomeric matrix protein 568 
(COMP) or thrombospondin-1 (TSP-1),32,33 i.e. putative ADAMTS7 substrates expressed in vascular 569 
tissue. Genetic variation at ADAMTS7, however, has no relationship with traditional risk factors or 570 
mechanistic biomarkers; hence the directional impact of ADAMTS7 expression on CHD risk and the 571 
underlying biological mechanisms have been unclear.32 572 
Our gene-smoking interaction analyses provide novel insights into the directional impact of 573 
the ADAMTS7 locus on CHD, the underlying mechanisms of CHD in smokers, and how such 574 
findings ultimately might translate towards achieving health benefits in society. Our human eQTL 575 
interrogations reveal that common alleles that relate to lower CHD risk at the ADAMTS7 locus are 576 
also associated with reduced ADAMTS7 expression, implying an atherogenic role of the gene. This 577 
is supported by our recent in vivo experimental studies; Adamts7 deficiency protected against diet-578 
induced atherosclerosis in both the Ldlr-/- and ApoE-/- mouse models, reduced neointima formation 579 
following arterial injury, and decreased VSMC migration in vitro.33 In our smoking-stratified analyses, 580 
we observed CHD protective effect which was attenuated in smokers. Thus, smoking exposure may 581 
overcome the genetic effect of protective alleles that act by reducing ADAMTS7 expression. Such a 582 
possibility is supported by our HCASMC data that reveals increased ADAMTS7 expression in 583 
HCASMC exposed to cigarette smoke extract. These human genome-smoking studies are the first to 584 
implicate a specific locus as causal in mediating increased risk of CHD in smokers. Additional 585 
translational studies are needed to establish the precise mechanisms of atheroprotection for alleles 586 
at the ADAMTS7 locus, how cigarette smoking impacts these genetic effects, and whether deletion 587 
or inhibition of ADAMTS7 in vivo attenuates the specific acceleration of atherosclerosis conferred by 588 
cigarette smoking.  589 
Strengths and limitations of our study merit consideration. This is a large study that 590 
conducted gene-smoking interaction analyses in CHD by using GWAS data. We observed 591 
substantial heterogeneity across study samples in our initial quality control analyses of “ever-592 
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smoking” status with CHD risk. This is similar, however, to the heterogeneity reported in a recent 593 
meta-analysis that pooled risk ratios from all the past prospective studies with information on 594 
association of “ever-smoking” with incident CHD events.5 We recognize that other smoking related 595 
phenotypes are important e.g., “current smoking” may have a more pronounced role than “ever-596 
smoking” in plaque rupture and thrombosis in patients with MI. We were however unable to 597 
distinguish between “former” versus “current” smokers within “Ever Smokers” in our current 598 
analyses; furthermore we were not able to analyze graded exposure to cigarette smoking such as 599 
“pack-years”. Given the use of multiple studies and meta-analyses of data, we used only one 600 
analytical approach to investigate gene-smoking interactions. This approach, however, was feasible 601 
and powerful in this large-scale consortium setting. While we used a fixed effects approach in our 602 
meta-analyses, a random effects meta-analysis yielded qualitatively similar results (data not shown). 603 
The lack or replication is partially offset by a large sample size, consistency across study cohorts 604 
and racial groups and supplemental genomic and experimental evidence supporting biological 605 
plausibility. This approach is also consistent with recent recommendations37 which favor use of a 606 
powerful discovery experiment using all data rather than reducing power by splitting available 607 
dataset for discovery and validation. While our in vitro studies support a role for ADAMTS7 in the 608 
gene-smoking interaction, it will be important to confirm that Adamts7 deficiency protect against 609 
cigarette-smoke acceleration of atherosclerosis in rodent models.  610 
Our interaction analyses, conditional analyses, eQTL interrogations and cell studies 611 
suggest that ADAMTS7, but not the CHRNB4-A3-A5 gene cluster, is likely causal at 15q21.1 for 612 
gene-smoking interaction effects in CHD. Yet, analyses are not definitive. Although top interacting 613 
SNPs and CHD SNPs (e.g., rs7178051) were associated with ADAMTS7, but not CHRNB4-A3-A5, 614 
expression in LCLs, large-scale eQTL data and allele specific expression data (e.g., via RNA 615 
sequencing) are not available for vascular tissues limiting causal inference. In our small HCAEC 616 
datasets, we did however find that alleles at rs7178051 associate with ADAMTS7 expression but not 617 
with any CHRNB4-A3-A5 genes suggesting, at least in one vascular cell type, that the gene-smoking 618 
interaction is mediated via ADAMTS7.  619 
 620 
 621 
 622 
 623 
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 624 
Conclusions 625 
We provide novel evidence for allelic variation exhibiting gene-smoking interaction in CHD 626 
at the chr.15q21.1 locus. The protective effect conferred by variation at this locus in never-smokers 627 
is markedly attenuated in people who are ever-smokers. Stepwise conditional analyses, gene 628 
expression data in vascular cells, eQTL interrogation, and cigarette smoke extract exposure in 629 
HCASMC suggest that ADAMTS7 accounts for both the gene-smoking interaction in CHD and the 630 
CHD main effect on chr.15q21.1. Our findings reveal interactions of genetic variants and key lifestyle 631 
determinants in the etiology of CHD, provide new insights into the potential mechanisms of CHD in 632 
cigarette smokers, and facilitate precision medicine advances in cigarette-smoking related CHD. Our 633 
work motivates future large-scale studies investigating joint effects of genes and environment in 634 
CHD using existing complex-disease consortia datasets and genome-wide discovery approaches. 635 
This will provide opportunities to detect additional and novel loci displaying gene-environment 636 
interactions revealing genetic contexts for targeting intensive lifestyle interventions and novel 637 
therapeutics. 638 
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 Table-1. Novel genotype-smoking interaction findings in coronary heart disease at the chromosome 15q25.1 locus  1098 
      Never Smokers  Ever Smokers   
Variant Association allele LD with 
rs7178051* 
LD with 
rs1051730^ 
 N 
cases 
N 
controls 
N 
Total 
Beta (SE) P-value  N 
cases 
N 
controls 
N 
Total 
Beta (SE) P-value  P-value 
interaction 
*rs71780514 CHD (NPR) T/C - 0.22  21232 38713 59945 -0.13 (0.01) 1.30E-16  39585 40749 80334 -0.05 (.01) 2.49E-04  8.57E-05 
†rs105173016 SB (known) A/G 0.22 -  20559 38198 58757 -0.04 (0.02) 0.02  38923 40371 79294 0.03 (0.01) 0.02  2.37E-04 
Other variants on chr.15q25.1 with significant gene-smoking interactions on CHD 
rs71737431 CHD (Known) C/T 0.61 0.18  21050 37955 59005 -0.11 (0.01) 2.73E-13  39044 39559 78603 -0.04 (0.01) 8.60E-04  9.29E-05 
rs100836962 CHD (Novel) A/G 1.0 0.22  19721 36206 55927 -0.11 (0.02) 1.60E-12  38807 40018 78825 -0.05 (0.01) 2.72E-04  5.15E-05 
rs71761873 CHD (Novel) T/C 1.0 0.24  21232 38713 59945 -0.12 (0.01) 7.02E-16  39585 40749 80334 -0.04 (0.01) 8.64E-04  6.93E-05 
rs64953355 CHD (Novel) G/T 1.0 0.22  20144 37217 57361 -0.13 (0.02) 2.39E-15  36448 38203 74651 -0.04 (0.01) 1.69E-03  9.51E-04 
rs43800286 CHD (Known) T/C 1 0.22  21232 38713 59945 -0.12 (0.01) 2.20E-15  39585 40749 80334 -0.04 (.01) 1.03E-03  5.44E-04 
rs38258077 CHD (Known) G/A 0.52 0.43  17137 28633 45771 -0.09 (0.02) 2.82E-08  30071 29014 59086 -0.03 (0.01) 0.04  2.6E-03 
rs38135658 CHD (NPR) T/G 0.43 0.56  19466 35830 55296 -0.08 (0.02) 5.08E-07  36642 37759 74401 -0.01 (0.01) 0.42  3.05E-04 
rs116384909 CHD (NPR) T/C 0.44 0.51  20465 37897 58362 -0.08 (0.01) 6.90E-08  38533 39690 78223 -0.01 (0.01) 0.28  2.25E-04 
rs1107279111 CHD (NPR) A/C 0.44 0.51  19289 35944 55233 -0.08 (0.02) 2.83E-07  35245 36635 71880 -.005 (0.01) 0.68  1.06E-04 
rs92269212 CHD (NPR) A/C 0.44 0.50  20559 38198 58757 -0.08 (0.01) 2.81E-07  38923 40371 79294 -0.01 (0.01) 0.29  2.75E-04 
rs1163837213 CHD (NPR) T/C 0.44 0.50  21232 38713 59945 -0.08 (0.01) 6.92E-08  39585 40749 80334 -0.01 (0.01) 0.23  3.16E-04 
rs488707714 CHD (NPR)  T/C 0.44 0.50  21232 38713 59945 -0.08 (0.01) 4.71E-08  39585 40749 80334 -0.02 (0.01) 0.20  3.92E-05 
rs1289913515 CHD (NPR) G/A 0.39 0.56  20377 37440 57817 -0.07 (0.02) 3.97E-06  38382 39181 77563 -0.01 (0.01) 0.58  4.54E-04 
rs68451318 SB (Known) C/G 0.01 0.10  12517 21054 33572 -0.01 (0.02) 0.67  24641 24487 49129 0.03 (0.02) 0.18  0.08 
rs203652719 SB (Known) A/G 0.17 0.90  20559 38198 58757 -0.04 (0.02) 0.02  38923 40371 79294 0.03 (0.01) 0.02  2.14E-04 
rs1051920320 CHD (NPR) G/A 0.19 0.93  21232 38713 59945 -0.04 (0.01) 5.93E-03  39585 40749 80334 0.03 (0.01) 0.03  1.27E-04 
rs803419121 SB (Known) C/T 0.19 1.0  19251 32131 51382 -0.05 (0.02) 2.62E-03  34925 34047 68972 0.02 (0.01) 0.06  3.91E-05 
                      CHD = coronary heart disease;  SB = smoking behavior; NPR: Not a previously reported variant with disease risk 1099
                     *lead variant in association with CHD in our dataset; † lead variant in association with SB 1100
1-21each number refers to the physical location of the variant in figure- 1101 
 1102 
 1103 
 1104 
 1105 
 1106 
 1107 
 1108 
 1109 
 1110 
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Figure Legends 1111 
 1112 
Figure 1. (a) Regional association analyses at the chromosome 15q25.1 locus in association with 1113 
CHD risk stratified by smoking status. Association P-values for genetic variants with CHD risk in 1114 
“never-smokers” (green squares) and “ever-smokers” (red triangles). (b) Longitudinal bars represent 1115 
gene-smoking CHD interaction P-values at the chromosome 15q25.1 locus; bars in blue are P-1116 
values for variants listed in Table-1 and each variant has been assigned a unique identification 1117 
number based on its physical location; (c) LD-blocks at the 15q25.1 locus visualized through 1118 
HAPLOVIEW using LD estimates in the HapMAP-2 CEU reference population.  1119 
 1120 
Figure 2. Several variants at chromosome 15q21.1 have stronger effects on CHD risk in “never-1121 
smokers” compared to “ever-smokers”. Variants with the strongest interaction P-value are displayed. 1122 
 1123 
Figure 3. Step-wise conditional analysis of genetic variation at the chromosome 15q21.1 locus with 1124 
CHD (red triangles) and smoking behavior (cigarettes per day, CPD; grey circles). At the 1125 
chromosome 15q21.1 locus, analyses adjusted for rs7178051 and rs11072794 completely 1126 
attenuated the gene-CHD associations whereas gene-smoking remained unchanged. Analyses 1127 
adjusted for rs1051730 and rs684513 completely attenuated the gene-smoking associations 1128 
whereas gene-CHD effect remained unchanged. 1129 
Figure 4. Analyses mutually adjusted for rs7178051, rs11072794, rs1051730 and rs684513 at 1130 
15q21.1 on CHD and smoking behavior; gene-CHD interaction analyses were only found significant 1131 
for rs7178051. Analyses on the left panel show associations of rs7178051, rs11072794, rs1051730 1132 
and rs684513 with CHD risk mutually adjusted for each other. Analyses on the right panel show 1133 
associations of rs7178051, rs11072794, rs1051730 and rs684513 with smoking behavior mutually 1134 
adjusted for each other. 1135 
Figure 5.  (a) ADAMTS7 and CHRNB4-A3-A5 mRNA levels were measured in HCASMC. Cells were 1136 
cultured to confluence, total RNA was extracted and cDNA generated. q-PCR was performed for 1137 
ACTB, GAPDH, TBP, ADAMTS7, CHRNB4, CHRNA3, CHRNA5 (95°C 15s, 60°C 1min). Delta Cts 1138 
were calculated as follows:  (CtACTB + CtGAPDH + CtTBP)/3 – CtTARGET GENE). Fold changes are derived 1139 
from delta delta Cts based on formula FC = 2-dCt. (b) Confluent HCASMC were exposed to cigarette 1140 
smoke extract. Serum starved (x24 hrs.) confluent HCASMC were treated with 0.5% or 1.0% 1141 
cigarette smoke extract  (v/v) for 4, 12, and 24 hrs. in serum reduced conditions (0.5% FBS in 1142 
DMEM). Total RNA was extracted, cDNA generated preparation and q-PCR performed for 1143 
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ADAMTS7 by Taqman and normalized to GAPDH. The Average Ct for ADAMTS7 at baseline was 1144 
28.25. Results were presented as means ± SEM, and data were analyzed using Student’s t-Test. (c) 1145 
expression and eQTL Data from the GTEx consortium, the HapMap consortium (restricted to 1146 
European populations), the Multiple Tissue Human Expression Resource (MuTHER) and in 147 1147 
donor HAoEC lines. Association of the independent lead variants identified in our conditional 1148 
analyses with expression of ADAMTS7 and genes in the CHRNB4-A3-A5 cluster. A P-value 1149 
threshold of 0.002 was set to account for multiple testing involved in the eQTL analyses. 1150 
Figure 6.  Genome browser view of regulatory features at rs7178051 on Chr15q21.1.  ChIP-seq 1151 
experiments were performed on confluent HCASMC for TCF21, Jun, JunD, CEBP and H3K4me1, 1152 
H3K27me3, H3K27ac. DNAaseI hypersensitivity data for human AoSMC were acquired from the 1153 
ENCODE project.  Human aortic tissue H3K4me1, H3K9me3, H3K27me3, and H3K36me3 ChIP-seq 1154 
data were acquired from the NIH Roadmap Epigenomics Project.  HCASMC = human coronary 1155 
artery smooth muscle cells; AoSMC = human aortic smooth muscle cells.   1156 
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